The nuclear receptor coactivator 3 (*NCOA3*, also known as *AIB1*) is a coactivator of nuclear receptors like the estrogen receptor. *NCOA3*is overexpressed in \~60% of primary human breast tumours, and high levels of *NCOA3*expression are associated with tamoxifen resistance and worse survival rate. In contrast, *NCOA3*deficiency suppresses *v*-Ha-*ras*-induced breast cancer initiation and progression in mice. Here we analysed the influence of *NCOA3*coding single nucleotide polymorphisms on breast cancer risk by performing a case--control study using a German and a Polish study population, and identified an association between *NCOA3*polymorphisms and breast cancer. A joint analysis of the German and Polish study population revealed a significant protective effect for the 1758G\>C (Q586H) and 2880A\>G (T960T) variants. In addition, haplotype analysis showed a protective effect of the 1758C-2880A and 1758G-2880G haplotypes (odds ratio = 0.79, 95% confidence interval = 0.67-0.93, *P*= 0.004). Due to the impact of *NCOA3*in anti-estrogen therapy resistance, these polymorphisms might also influence therapy outcome in breast cancer.
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